Trial ID 21461 | Maryland Oncology Hematology Trial ID 21461 – Maryland Oncology Hematology

Trial ID 21461

Trial Information - Phase III

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

Protocol ID: MK-3475-C93/GOG-3064

Sponsor: GOG Foundation /Merck & Co., Inc.

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Endometrial

Investigator

Aylesworth MD, Cheryl

Status

OPEN TO ENROLLMENT

Sponsor

GOG Foundation /Merck & Co., Inc.

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology